[Form 4] Teladoc Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Teladoc Health’s chief legal officer Adam C. Vandervoort reported a mix of equity awards, vesting and a related share sale. On March 2, he sold 27,083 shares of common stock at $5.117 per share to cover tax withholding obligations tied to recently vesting awards. Following this sale, he directly owned 103,239 common shares.

On March 1, he received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc common share. Around February 27, multiple restricted stock unit and performance stock unit awards converted into common stock on a one-for-one basis, and he also earned 5,107 performance stock units based on metrics related to the company’s 2025 financial results.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vandervoort Adam C

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER, SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		M		4,418	A	(1)	85,150	D
Common Stock	02/27/2026		M		5,350	A	(1)	90,500	D
Common Stock	02/27/2026		M		36,610	A	(1)	127,110	D
Common Stock	02/27/2026		M		1,510	A	(2)	128,620	D
Common Stock	02/27/2026		M		1,702	A	(2)	130,322	D
Common Stock	03/02/2026		S		27,083(3)	D	$5.117	103,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/27/2026		M			4,418	(4)	(4)	Common Stock	4,418	$0	0	D
Restricted Stock Units	(1)	02/27/2026		M			5,350	(5)	(5)	Common Stock	5,350	$0	21,400	D
Restricted Stock Units	(1)	02/27/2026		M			36,610	(6)	(6)	Common Stock	36,610	$0	73,222	D
Performance Stock Units	(2)	02/27/2026		M			1,510	(7)	(7)	Common Stock	1,510	$0	0	D
Performance Stock Units	(8)	02/27/2026		A		5,107(9)		(10)	(10)	Common Stock	5,107	$0	5,107	D
Performance Stock Units	(2)	02/27/2026		M			1,702	(11)	(11)	Common Stock	1,702	$0	3,405	D
Restricted Stock Units	(12)	03/01/2026		A		181,661		(13)	(13)	Common Stock	181,661	$0	181,661	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

4. On March 3, 2023, the reporting person was granted 53,013 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

5. On March 19, 2024, the reporting person was granted 64,200 restricted stock units, vesting one-third on March 19, 2025, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

6. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

7. On March 1, 2024, the reporting person earned 18,067 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

8. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.

9. Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.

10. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

11. On March 1, 2026, the reporting person earned 5,107 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

12. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.

13. One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.